Zai Lab and Novocure Report Positive Phase III Results for TTFields in NSCLC Brain Metastases
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, and Novocure...
Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai
Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China,...
Jiangsu Hengrui Receives NMPA Approval for SHR-7631 ADC Clinical Study in Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...
Acotec Scientific Receives NMPA Approval for Innovative Cardiovascular Devices
Acotec Scientific Holdings Ltd (HKG: 6669), a leading medical device company based in China, has...
Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools
Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China...
WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions
WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Alexion’s Ultomiris Secures FDA Approval for Anti-AQP4 Positive NMOSD Treatment
AstraZeneca’s (AZ; NASDAQ: AZN) rare disease unit, Alexion, has registered its biologic Ultomiris (ravulizumab) with...
NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances
The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...
Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline
AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company...
National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023
The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling...
MSD’s Winrevair Approved by FDA as First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
The US Food and Drug Administration (FDA) has granted Merck, Sharp & Dohme (MSD; NYSE:...
China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends
The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...
Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released...
Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting...
Shanghai Pharmaceuticals, SHC, and CEMCS CAS Renew Partnership to Incubate Pharmaceutical Innovations
Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...
Kobayashi Pharmaceutical Recalls Red Yeast Rice Pills in China Amid Health Concerns
Japan-based Kobayashi Pharmaceutical has reportedly initiated a product recall in the Chinese market for its...